Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.08 USD | +0.97% | +9.47% | -30.43% |
Mar. 25 | Esperion Shares Continue Rise After Friday's FDA Approval for Nexlizet, Nexletol | DJ |
Mar. 25 | Sector Update: Health Care Stocks Steady Premarket Monday | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-30.43% | 390M | |
+26.08% | 681B | |
+21.85% | 556B | |
-4.77% | 361B | |
+16.97% | 325B | |
+5.69% | 285B | |
+13.68% | 235B | |
+3.65% | 199B | |
-11.12% | 189B | |
-3.40% | 157B |
- Stock Market
- Equities
- ESPR Stock
- News Esperion Therapeutics, Inc.
- Credit Suisse Lowers Esperion Therapeutics' PT to $8 from $11 on Heels of Dilutive Secondary Financing, Keeps Neutral Rating